Discovery of antibody biomarkers for Alzheimer’s Disease

阿尔茨海默病抗体生物标志物的发现

• 批准号: 9265411
• 负责人: Thomas J. Kodadek
• 金额: $ 19.2万
• 依托单位: SCRIPPS FLORIDA
• 依托单位国家: 美国
• 财政年份: 2016
• 资助国家: 美国
• 起止时间: 2016-05-01 至 2018-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9265411
• 关键词: Adaptive Immune System; Affinity; Alzheimer disease detection; Alzheimer' s Disease; Antibodies; Antibody Binding Sites; Antigens; Binding; Binding Sites; Biological Assay; Biological Markers; Biology; Blood; Blood Tests; Dementia; Development; Diagnosis; Diagnostic; Diagnostic Sensitivity; Diagnostic Specificity; Disease; Epitopes; Generations; Goals; Immobilization; Individual; Investigation; Laboratories; Lead; Libraries; Ligands; Light; Medical; Methods; Molecular Conformation; Neurodegenerative Disorders; Pathology; Patients; Sampling; Serum; Source; System; Testing; Validation; Work; antigen binding; biomarker discovery; clinically relevant; combinatorial; diagnostic assay; experimental study; follow-up; hydrophilicity; novel; public health relevance; screening; specific biomarkers

 DESCRIPTION (provided by applicant): The discovery of serum biomarkers for Alzheimer's disease (AD) represents an enormous unmet medical need. This project will further explore the hypothesis that the adaptive immune system might react to unusual antigens produced as a result of AD pathology and as a result produce high levels of antibodies that would not be found in a normal individual. There is some evidence that this is the case. To discover these antibodies we plan to screen large libraries of bead-displayed synthetic oligomers and find compounds that retain far more antibodies from AD serum samples than from controls. These molecules would be employed as first generation "capture agents" for the AD-specific antibodies in a multiplexed Luminex-like diagnostic assay. If this R21 preliminary investigation is successful, it would set the stage for compound optimization and a much larger validation trial that could lead to an effective blood test for AD.

 描述（由适用提供）：针对阿尔茨海默氏病（AD）发现血清生物标志物（AD）代表了巨大的未满足的医疗需求。该项目将进一步探讨以下假设：自适应免疫系统可能会对由于AD病理学而产生的异常抗原做出反应，因此产生了高水平的抗体，这些抗体在正常个体中找不到。有证据表明情况。为了发现这些抗体，我们计划筛选大型珠状合成寡聚物的库，并找到与对照组相比，它们保留了AD血清样品中更多抗体的化合物。这些分子将用作多重Luminex样诊断测定法中AD特异性抗体的第一代“捕获剂”。如果此R21初步研究成功，它将为复合优化和更大的验证试验奠定基础，这可能会导致AD的有效血液测试。

项目成果

Asymmetric synthesis of vinylogous β-amino acids and their incorporation into mixed backbone oligomers.

• DOI: 10.1039/c7ob00333a
• 发表时间: 2017-04-11
• 期刊: Organic & biomolecular chemistry
• 影响因子: 3.2
• 作者: Wu H;An H;Mo SC;Kodadek T
• 通讯作者: Kodadek T

Cell-Permeable Peptides Containing Cycloalanine Residues.

• DOI: 10.1002/anie.201605745
• 发表时间: 2016-10-04
• 期刊: ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
• 影响因子: 16.6
• 作者: Wu, Hao;Mousseau, Guillaume;Mediouni, Sonia;Valente, Susana T.;Kodadek, Thomas
• 通讯作者: Kodadek, Thomas